Home › Products › Gene function › Viral transduction › Lentivirus › Vector systems › Tet-inducible

Lentivirus

Lentiviral Tet-One inducible expression systems

The Tet-One system allows you to generate inducible expression systems as easily as you would generate constitutive expression systems. Previous inducible expression systems required transduction of two separate vectors into your cells. With the Tet-One system, both the doxycycline-responsive transactivator and your gene of interest are combined on the same vector. This allows for an easier setup while maintaining the low background expression and up to 25,000-fold induction (Heinz et al. 2011) in response to doxycycline that is found in the Tet-On 3G systems.

Lenti-X Packaging Single Shots (VSV-G), a high-titer fourth-generation packaging system, is included with each Lenti-X Tet-One kit.

More Less

Cat. #

Product

Size

Price

License

Quantity

Details

631844

Lenti-X™ Tet-One™ Inducible Expression System

Each

$1768.00

License Statement

ID Number
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 7541446, # 8383364, # 9181556 , European patents EP # 1200607, # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Tet-One Inducible Expression System is a tetracycline-inducible lentiviral gene expression system that allows you to produce high titers of recombinant, VSV-G-pseudotyped lentiviruses for the purpose of establishing a tightly inducible expression system for your gene of interest in a wide variety of dividing and non-dividing mammalian cells. The all-in-one pLVX-TetOne Vector expresses the Tet-On 3G transactivator from the constitutive human PGK promoter in the forward orientation and your gene of interest from the P_TRE3GS promoter in the reverse orientation. In the presence of doxycycline (Dox), the Tet-On 3G transactivator specifically binds and activates high-level transcription from the inducible promoter that controls expression of your gene. This vector does not contain a selection marker. The kit also includes Lenti-X Packaging Single Shots (VSV-G), a complete fourth generation lentiviral packaging system, and a sample of Lenti-X GoStix.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Components

Required Products

Cat. #	Product	Size	Price
631106	Tet System Approved FBS	500 mL	$865.00
Fetal Bovine Serum (FBS) that has been functionally tested for optimal use with all of our Tet Systems. This FBS does not contain trace levels of tetracycline (or its derivatives) which have been observed to interfere with proper regulation of TRE-controlled gene expression. Use of this serum ensures the maximal range of induction possible with the Tet Systems. Documents Components Image Data Back Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems Fetal bovine serum (FBS) approved for use with tetracycline inducible expression systems. Only Takara Bio USA functionally tests FBS to be sure that no contaminating tetracycline derivatives interfere with induced expression levels.
631101	Tet System Approved FBS, US-Sourced	500 mL	$875.00
Fetal Bovine Serum (FBS) that has been functionally tested for optimal use with all of our Tet Systems. This FBS does not contain trace levels of tetracycline (or derivatives) which have been observed to interfere with proper regulation of TRE-controlled gene expression. Use of this serum ensures the maximal range of induction possible with the Tet Systems. This FBS has been processed in the United States. Documents Components Image Data Back Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems Fetal bovine serum from Clontech is functionally tested to guarantee consistent results with tetracycline-inducible expression systems. Serum from other vendors that have not been functionally tested may contain tetracyclines that affect the maximum expression in Tet-Off systems, or generate background in Tet-On systems. Data here shows induction of luciferase expression from our CHO-AA8-Luc Tet-Off Control Cell Line using different sources of FBS.

631847

Lenti-X™ Tet-One™ Inducible Expression System (Puro)

Each

$1768.00

License Statement

ID Number
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 7541446, # 8383364, # 9181556 , European patents EP # 1200607, # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.

The Lenti-X Tet-One Inducible Expression System (Puro) is a tetracycline-inducible lentiviral gene expression system that allows you to produce high titers of recombinant, VSV-G pseudotyped lentiviruses for the purpose of establishing a tightly inducible expression system for your gene of interest in a wide variety of dividing and non-dividing mammalian cells. The all-in-one pLVX-TetOne-Puro Vector expresses the Tet-On 3G transactivator from the constitutive human PGK promoter in the forward orientation and your gene of interest from the P_TRE3GS promoter in the reverse orientation. In the presence of doxycycline (Dox), the Tet-On 3G transactivator specifically binds and activates high-level transcription from the inducible promoter that controls expression of your gene. In addition, this vector contains a puromycin antibiotic selection marker. The kit also includes Lenti-X Packaging Single Shots (VSV-G), a complete fourth generation lentiviral packaging system, and a sample of Lenti-X GoStix.

Notice to purchaser

Components

Required Products

Cat. #	Product	Size	Price
631106	Tet System Approved FBS	500 mL	$865.00
Fetal Bovine Serum (FBS) that has been functionally tested for optimal use with all of our Tet Systems. This FBS does not contain trace levels of tetracycline (or its derivatives) which have been observed to interfere with proper regulation of TRE-controlled gene expression. Use of this serum ensures the maximal range of induction possible with the Tet Systems. Documents Components Image Data Back Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems Fetal bovine serum (FBS) approved for use with tetracycline inducible expression systems. Only Takara Bio USA functionally tests FBS to be sure that no contaminating tetracycline derivatives interfere with induced expression levels.
631101	Tet System Approved FBS, US-Sourced	500 mL	$875.00
Fetal Bovine Serum (FBS) that has been functionally tested for optimal use with all of our Tet Systems. This FBS does not contain trace levels of tetracycline (or derivatives) which have been observed to interfere with proper regulation of TRE-controlled gene expression. Use of this serum ensures the maximal range of induction possible with the Tet Systems. This FBS has been processed in the United States. Documents Components Image Data Back Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems Fetal bovine serum from Clontech is functionally tested to guarantee consistent results with tetracycline-inducible expression systems. Serum from other vendors that have not been functionally tested may contain tetracyclines that affect the maximum expression in Tet-Off systems, or generate background in Tet-On systems. Data here shows induction of luciferase expression from our CHO-AA8-Luc Tet-Off Control Cell Line using different sources of FBS.

*You must be logged in to a Business Account in order to purchase these products online, since the purchase of these products may be restricted depending on your account type. Researchers at not-for-profit accounts receive a limited use license with their purchase of the product. Researchers at for-profit accounts must obtain a license prior to purchase. For details please contact licensing@takarabio.com.

Overview

Highly efficient Lenti-X Packaging Single Shots (VSV-G), (included) generates high titers with a very high safety profile
Tightly controlled expression of your gene of interest with the TRE3G promoter
Simple, single-vector design
Option to use a puromycin resistance cassette to select for stable clones
Tet-Express systems and Tet-On 3G lentiviral systems are also available
Tetracycline-inducible expression in the widest range of hard-to-transfect cell types

More Information

References

Heinz, N., Schambach, A., Galla, M., Maetzig, T., Baum, C., Loew R. & Schiedlmeier, B. Retroviral and transposon-based Tet-regulated all-in-one vectors with reduced background expression and improved dynamic range. Hum. Gene Ther. 22, 166–176 (2011).

Additional product information

Please see the product’s Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.

Lenti-X Concentrator video

Lenti-X Concentrator is a simple and fast method for concentrating any lentiviral stock—just mix your lentiviral supernatant with the concentration reagent, incubate, and spin the mixture in a standard centrifuge. Watch the video to see how it works.

Watch Concentrator video Lentiviral packaging overview

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

Lentiviral Tet-One inducible expression systems

Notice to purchaser

Seven out of eight Tet-One clones show more than 1,000-fold induction of expression

The Tet-One system is highly sensitive to low levels of doxycycline (Dox)

Lenti-X Tet-One Vector maps

Tet-One System Mechanism — The Tet-On 3G transactivator protein is expressed constitutively from the human PGK promoter (PPGK) but is unable to bind to the TRE3G promoter (PTRE3G) in the absence of doxycycline (Dox)

Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems

Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems

Notice to purchaser

Seven out of eight Tet-One clones show more than 1,000-fold induction of expression

The Tet-One system is highly sensitive to low levels of doxycycline (Dox)

Lenti-X Tet-One Vector maps

Tet-One System Mechanism — The Tet-On 3G transactivator protein is expressed constitutively from the human PGK promoter (PPGK) but is unable to bind to the TRE3G promoter (PTRE3G) in the absence of doxycycline (Dox)

Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems

Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems

Overview

More Information

References

Additional product information